<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1110">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409886</url>
  </required_header>
  <id_info>
    <org_study_id>120-20-ASF</org_study_id>
    <nct_id>NCT04409886</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients</brief_title>
  <acronym>HBOT</acronym>
  <official_title>The Application of Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients - Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomized controlled, double blind clinical trial performed on
      laboratory confirmed COVID-19 infection admitted patients in the Shamir Medical Center. The
      trial will include 30 patients who will undergo either hyperbaric oxygen therapy (HBOT) or
      Normobaric oxygen therapy (NBOT), randomized on a 2:1 ratio, within 4 days in addition to the
      standard treatment including oxygen, drugs, steroids, bronchodilators, antibiotics and
      others.

      The evaluation procedure includes symptom monitoring, room air saturation, vital signs
      monitoring, pulmonary function and blood tests at baseline, one day and one week after the
      last session. In addition, one hour prior to and post session saturation and vitals will be
      monitored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective randomized controlled, double blind clinical trial performed on
      laboratory confirmed COVID-19 infection admitted patients at MMC. The trial will include 30
      patients who will undergo either HBOT or NBOT, randomized on a 2:1 ratio, within 4 days in
      addition to the standard treatment including oxygen, drugs, steroids, bronchodilators,
      antibiotics and others.

      Sessions will be provided in an MMC monoplace HBO chamber (RestorixHealth). Since all
      patients demand oxygen supply at room air, the control group is an active arm receiving 100%
      oxygen. For HBOT, each session will include breathing 100% oxygen at 2.2 absolute atmospheres
      (ATA) for 60 minutes. Compression and decompression will occur at 1 meter/minute rate. For
      NBOT, each session will include breathing 100% oxygen at 1.0 absolute atmospheres (ATA) for
      60 minutes. In order to blind the patient, the first 5 minutes will include compression for
      1.1 ATA and then decompression to 1.0 within the next 5 minutes.

      During the sessions, the symptoms and vitals will be monitored. The evaluation procedure will
      include symptom monitoring, room air saturation, vital signs monitoring, pulmonary function
      and blood tests at baseline, one day and one week after the last session. In addition, one
      hour prior to and post session saturation and vitals will be monitored. Sessions and
      evaluations procedures will occur as the following:

      Protocol Day 1

        1. Baseline evaluation: blood test including: arterial blood gases, 2 CBC tubes, 2 Gel
           tubes (10-15 cc total), vitals (temperature, blood pressure, heart rate, room air
           saturation), symptoms questionnaire, pulmonary function test.

        2. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour prior to
           session

        3. One-hour session NBO/HBO

        4. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour after the
           session.

        5. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour before the
           2nd session.

        6. One-hour session NBO/HBO (8 hours following the first session)

        7. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour after the
           session.

        8. Daily oxygen supply dose monitoring. Protocol Day 2-4

      1. Daily symptoms questionnaire 2. Vitals (temperature, blood pressure, heartrate, room air
      saturation) one hour prior to session One-hour session NBO/HBO 3. Vitals (temperature, blood
      pressure, heartrate, room air saturation) one hour after the session.

      4. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour before the
      2nd session.

      5. One-hour session NBO/HBO (8 hours following the first session) 6. Vitals (temperature,
      blood pressure, heartrate, room air saturation) one hour after the session.

      7. Daily oxygen supply dose monitoring. Follow up Protocol

        1. Repeat evaluations one day after the last session and one week after the last session:

             -  Blood test including: arterial blood gases, 2 CBC tubes, 2 Gel tubes (10-15 cc
                total)

             -  Vitals (temperature, blood pressure, heart rate, room air saturation)

             -  Symptoms questionnaire

             -  Pulmonary function test.

        2. Oropharyngeal swab for SARS-CoV-2 RT-PCR every 3 days for 1 week

        3. Clinical monitoring for 30 days
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenation index</measure>
    <time_frame>one day after the last session</time_frame>
    <description>PaO2/FiO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SpO2</measure>
    <time_frame>6 hours after a session</time_frame>
    <description>Room air saturation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>one week after the last session</time_frame>
    <description>Room air saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms level</measure>
    <time_frame>one week after the last session</time_frame>
    <description>COVID19 symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest Xray</measure>
    <time_frame>one week after the last session</time_frame>
    <description>Radiologic</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COVID, Coronavirus</condition>
  <arm_group>
    <arm_group_label>HBOT (Hyperbaric Oxygen Therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NBOT (Normobaric Oxygen Therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyperbaric Chamber</intervention_name>
    <description>Dives in a Hyperbaric Oxygen chamber</description>
    <arm_group_label>HBOT (Hyperbaric Oxygen Therapy)</arm_group_label>
    <arm_group_label>NBOT (Normobaric Oxygen Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Within 7 days of patient's need of oxygen supply

          -  Positive SARS-CoV-2 RT-PCR

          -  At least one risk factor for bad prognosis of COVID-19: hypertension, diabetes
             mellitus, ischemic heart disease, smoking, age&gt;50, etc.

          -  Respiratory insufficiency: Room Air SpO2 &lt;94% or PaO2/FiO2&lt;300mmHg

          -  Age&gt;18

          -  Ability to sign an informed consent

        Exclusion Criteria:

          -  Negative SARS-CoV-2 RT-PCR

          -  HBOT contraindication: pneumothorax, pneumomediastinum, claustrophobia, ear/sinus
             disease which aren't allowed in HBOT, known chronic pulmonary disease: severe
             emphysema or known pulmonary bullae.

          -  Pregnancy

          -  Inability to sign an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ory Wiesel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ory Wiesel, MD</last_name>
    <phone>718-283-7936</phone>
    <email>owiesel@maimonidesmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gene Sobol</last_name>
    <phone>718-283-2926</phone>
    <email>gsobol@maimonidesmed.org</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will not be shared</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT04409886/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

